Blood-based biomarkers for precision medicine in lung cancer: Precision radiation therapy

Dirk De Ruysscher, Jianyue Jin, Tim Lautenschlaeger, Jin Xiong She, Zhongxing Liao, Feng Ming Spring Kong

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Both tumors and patients are complex and models that determine survival and toxicity of radiotherapy or any other treatment ideally must take into account this variability as well as its dynamic state. The genetic features of the tumor and the host, and increasingly also the epi-genetic and proteomic characteristics, are being unraveled. Multiple techniques, including histological examination, blood sampling, measurement of circulating tumor cells (CTCs), and functional and molecular imaging, can be used for this purpose. However, the effects of radiation on the tumor and on organs at risk (OARs) are also influenced by the applied dose and volume of irradiated tissues. Combining all these biological, clinical, imaging, and dosimetric parameters in a validated prognostic or predictive model poses a major challenge. Here we aimed to provide an objective review of the potential of blood markers to guide high precision radiation therapy. A combined biological-mathematical approach opens new doors beyond prognostication of patients, as it allows truly precise oncological treatment. Indeed, the core for individualized and precision medicine is not only selection of patients, but even more the optimization of the therapeutic window on an individual basis. A holistic model will allow for determination of an individual dose-response relationship for each organ at risk for each tumor in each individual patient for the complete oncological treatment package. This includes, but is not limited to, radiotherapy alone. Individualized dose-response curves will allow for consideration of different doses of radiation and combinations with other drugs to plan for both optimal toxicity and complete response. Insights into the interactions between a multitude of parameters will lead to the discovery of new pathways and networks that will fuel new biological research on target discovery.

Original languageEnglish (US)
Pages (from-to)661-669
Number of pages9
JournalTranslational Lung Cancer Research
Volume6
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Precision Medicine
Lung Neoplasms
Radiotherapy
Biomarkers
Organs at Risk
Neoplasms
Histological Techniques
Circulating Neoplastic Cells
Molecular Imaging
Radiation Effects
Therapeutics
Proteomics
Patient Selection
Radiation
Survival
Research
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Lung cancer
  • Precision medicine
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Blood-based biomarkers for precision medicine in lung cancer : Precision radiation therapy. / De Ruysscher, Dirk; Jin, Jianyue; Lautenschlaeger, Tim; She, Jin Xiong; Liao, Zhongxing; Kong, Feng Ming Spring.

In: Translational Lung Cancer Research, Vol. 6, No. 6, 01.12.2017, p. 661-669.

Research output: Contribution to journalReview article

De Ruysscher, Dirk ; Jin, Jianyue ; Lautenschlaeger, Tim ; She, Jin Xiong ; Liao, Zhongxing ; Kong, Feng Ming Spring. / Blood-based biomarkers for precision medicine in lung cancer : Precision radiation therapy. In: Translational Lung Cancer Research. 2017 ; Vol. 6, No. 6. pp. 661-669.
@article{fed8bf641b784014834346ac2a317c1d,
title = "Blood-based biomarkers for precision medicine in lung cancer: Precision radiation therapy",
abstract = "Both tumors and patients are complex and models that determine survival and toxicity of radiotherapy or any other treatment ideally must take into account this variability as well as its dynamic state. The genetic features of the tumor and the host, and increasingly also the epi-genetic and proteomic characteristics, are being unraveled. Multiple techniques, including histological examination, blood sampling, measurement of circulating tumor cells (CTCs), and functional and molecular imaging, can be used for this purpose. However, the effects of radiation on the tumor and on organs at risk (OARs) are also influenced by the applied dose and volume of irradiated tissues. Combining all these biological, clinical, imaging, and dosimetric parameters in a validated prognostic or predictive model poses a major challenge. Here we aimed to provide an objective review of the potential of blood markers to guide high precision radiation therapy. A combined biological-mathematical approach opens new doors beyond prognostication of patients, as it allows truly precise oncological treatment. Indeed, the core for individualized and precision medicine is not only selection of patients, but even more the optimization of the therapeutic window on an individual basis. A holistic model will allow for determination of an individual dose-response relationship for each organ at risk for each tumor in each individual patient for the complete oncological treatment package. This includes, but is not limited to, radiotherapy alone. Individualized dose-response curves will allow for consideration of different doses of radiation and combinations with other drugs to plan for both optimal toxicity and complete response. Insights into the interactions between a multitude of parameters will lead to the discovery of new pathways and networks that will fuel new biological research on target discovery.",
keywords = "Biomarkers, Lung cancer, Precision medicine, Radiotherapy",
author = "{De Ruysscher}, Dirk and Jianyue Jin and Tim Lautenschlaeger and She, {Jin Xiong} and Zhongxing Liao and Kong, {Feng Ming Spring}",
year = "2017",
month = "12",
day = "1",
doi = "10.21037/tlcr.2017.09.12",
language = "English (US)",
volume = "6",
pages = "661--669",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "6",

}

TY - JOUR

T1 - Blood-based biomarkers for precision medicine in lung cancer

T2 - Precision radiation therapy

AU - De Ruysscher, Dirk

AU - Jin, Jianyue

AU - Lautenschlaeger, Tim

AU - She, Jin Xiong

AU - Liao, Zhongxing

AU - Kong, Feng Ming Spring

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Both tumors and patients are complex and models that determine survival and toxicity of radiotherapy or any other treatment ideally must take into account this variability as well as its dynamic state. The genetic features of the tumor and the host, and increasingly also the epi-genetic and proteomic characteristics, are being unraveled. Multiple techniques, including histological examination, blood sampling, measurement of circulating tumor cells (CTCs), and functional and molecular imaging, can be used for this purpose. However, the effects of radiation on the tumor and on organs at risk (OARs) are also influenced by the applied dose and volume of irradiated tissues. Combining all these biological, clinical, imaging, and dosimetric parameters in a validated prognostic or predictive model poses a major challenge. Here we aimed to provide an objective review of the potential of blood markers to guide high precision radiation therapy. A combined biological-mathematical approach opens new doors beyond prognostication of patients, as it allows truly precise oncological treatment. Indeed, the core for individualized and precision medicine is not only selection of patients, but even more the optimization of the therapeutic window on an individual basis. A holistic model will allow for determination of an individual dose-response relationship for each organ at risk for each tumor in each individual patient for the complete oncological treatment package. This includes, but is not limited to, radiotherapy alone. Individualized dose-response curves will allow for consideration of different doses of radiation and combinations with other drugs to plan for both optimal toxicity and complete response. Insights into the interactions between a multitude of parameters will lead to the discovery of new pathways and networks that will fuel new biological research on target discovery.

AB - Both tumors and patients are complex and models that determine survival and toxicity of radiotherapy or any other treatment ideally must take into account this variability as well as its dynamic state. The genetic features of the tumor and the host, and increasingly also the epi-genetic and proteomic characteristics, are being unraveled. Multiple techniques, including histological examination, blood sampling, measurement of circulating tumor cells (CTCs), and functional and molecular imaging, can be used for this purpose. However, the effects of radiation on the tumor and on organs at risk (OARs) are also influenced by the applied dose and volume of irradiated tissues. Combining all these biological, clinical, imaging, and dosimetric parameters in a validated prognostic or predictive model poses a major challenge. Here we aimed to provide an objective review of the potential of blood markers to guide high precision radiation therapy. A combined biological-mathematical approach opens new doors beyond prognostication of patients, as it allows truly precise oncological treatment. Indeed, the core for individualized and precision medicine is not only selection of patients, but even more the optimization of the therapeutic window on an individual basis. A holistic model will allow for determination of an individual dose-response relationship for each organ at risk for each tumor in each individual patient for the complete oncological treatment package. This includes, but is not limited to, radiotherapy alone. Individualized dose-response curves will allow for consideration of different doses of radiation and combinations with other drugs to plan for both optimal toxicity and complete response. Insights into the interactions between a multitude of parameters will lead to the discovery of new pathways and networks that will fuel new biological research on target discovery.

KW - Biomarkers

KW - Lung cancer

KW - Precision medicine

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85031325660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031325660&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2017.09.12

DO - 10.21037/tlcr.2017.09.12

M3 - Review article

AN - SCOPUS:85031325660

VL - 6

SP - 661

EP - 669

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 6

ER -